Therapy of difficult cases of canine pyoderma with marbofloxacin: a report of 39 dogs.
Thirty-nine dogs with severe and/or recurrent lesions of pyoderma were treated with marbofloxacin at an average dosage of 2.12 mg/kg bodyweight, once daily, for time periods varing from 10 to 213 days. Forty-seven strains of bacteria, isolated from 34 cultures, were tested for sensitivity to various antibiotics. At day 0, no resistance to marbofloxacin was found, but one refractory case, a strain of Staphylococcus intermedius resistant to marbofloxacin, was cultured at day 28. Thirty-three dogs (84.6 per cent) showed an excellent response (cure), one (2.6 per cent) a clear improvement and one (2.6 per cent) a smaller improvement, while the remaining four dogs showed no response after 11 to 60 days. Fifteen dogs (45.5 per cent) relapsed over the follow-up period of three to 191 days, but none of the dogs in the study exhibited any adverse effects.
Carlotti
D N
DN
Cabinet de Dermatologie Vétérinaire, Bordeaux-Mérignac, France.
Guaguere
E
E
Pin
D
D
Jasmin
P
P
Thomas
E
E
Guiral
V
V
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D001835:Body Weight; D002481:Cellulitis / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D004890:Erythema / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D005260:Female; D024841:Fluoroquinolones; D005499:Folliculitis / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D005500:Follow-Up Studies; D008297:Male; D008826:Microbial Sensitivity Tests; D011537:Pruritus / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D011711:Pyoderma / Q000188:drug therapy* / Q000382:microbiology / Q000662:veterinary*; D015363:Quinolones / Q000008:administration & dosage*; D012008:Recurrence; D012883:Skin Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D013203:Staphylococcal Infections / Q000188:drug therapy; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D004791:Enzyme Inhibitors; D024841:Fluoroquinolones; D015363:Quinolones; C080260:marbofloxacin